title: Althesin in the management of head injuries: a preliminary report.
abstract: The aggressive treatment of major craniocerebral trauma has received recent attention. Barbiturate administration has been beneficial in some cases of sustained, uncontrolled intracranial hypertension. One major disadvantage of pentobarbital narcosis is the long half-life of the drug (15 to 48 hours). We have used Althesin, an intravenous steroid anesthetic (alfaxalone and alfadolone acetate; Glaxo Laboratories Ltd., Greenford, Middlesex, England), in eight seriously head-injured patients. Althesin combines the theoretical advantages of pentobarbital in the management of head trauma with almost immediate reversibility (serum half-life, 1.6 minutes). Raised intracranial pressure and clinical outcome seem to be influenced favorably and the side effects are negligible when the drug is administered by continuous intravenous infusion over several days. Further study of this compound in the management of head trauma seems warranted.
mesh_terms: D000293:Adolescent; D000328:Adult; D000530:Alfaxalone Alfadolone Mixture / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D006259:Craniocerebral Trauma / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007427:Intracranial Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged
chemical_list: D000530:Alfaxalone Alfadolone Mixture